secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2022-09-16T23:59:59+00:00
Accession:  0001493152-22-026119
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce Biosciences CMO Dr. Nily Osman resigns; Dr. William Schmidt appointed interim CMO
--------------------------------------------------------------------------------

- Dr. Nily Osman resigned as Chief Medical Officer effective September 15, 2022.
- Dr. William K. Schmidt appointed interim Chief Medical Officer effective same date; he previously served as CMO from Jan 2016 to Apr 2022.
- Dr. Schmidt has over 25 years of pharma experience and led clinical development for Entereg (alvimopan) at Adolor Corporation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315222026119/0001493152-22-026119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315222026119/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-026119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer